EOD close · 19 Nov 2026
Range-bound — awaiting direction.
Now at 57% of its 52-week range
Last 30 sessions
-8.9%Phase indicator
Range-bound — awaiting direction.
Delivery conviction
Lifetime story
Windlas Biotech is up 383.6% from its lifetime low of ₹203.15 on 20 Jun 2022. ₹10,000 invested then would be worth ₹48,361 today (42.9% CAGR over 4.4 years). Lifetime high of ₹1197.00 was set on 6 Nov 2024 (currently -17.9% below).
30-day conviction trend
Fundamentals
Standalone vs consolidated — most retail products show only one. Consolidated includes subsidiary contribution.
| Standalone | Consolidated | |
|---|---|---|
| P/E (TTM) | 31.00 | 31.11 |
| P/B | 3.46 | 3.56 |
| Price / Cash flow | 21.22 | 21.27 |
| Dividend yield | 0.64% | 0.64% |
| Book value / share | 285.12 ₹ | 276.72 ₹ |
| EPS (TTM) | 31.77 ₹ | 31.66 ₹ |
Returns ladder
Disclosed to the exchange
Large trades in Windlas Biotech
Single large transactions, named by NSE the same evening. No mutual fund appears in this window.
latest 6 Nov 2026
- 6 Nov 2026bulk1,50,500₹1020.42₹15.4 CrBUYSTELLAR WEALTH PARTNERS INDIA FUND I LP
Source: NSE bulk and block deal disclosures, reproduced as reported. A deal is disclosed only when one party trades at least 0.5% of a company's shares in a day, or negotiates a block of ₹25 crore or more — so most institutional activity never appears here, and a stock with no rows has not necessarily been left alone. Where a trade qualified as both, it is shown once carrying both labels. NSE names the fund house, never the scheme, so no individual fund can be inferred from these rows. Value is quantity × the reported price, which for a bulk deal is a weighted average.
How this page is produced
Every figure above is computed from end-of-day exchange prices, snapshotted daily, closing 19 Nov 2026. Nothing here is copied from a factsheet or a third-party summary. The full method is published, including its limitations.
Written and maintained by Azad Mohammed, who built the pipeline these numbers come out of. Found an error? Tell us — corrections are made and the page rebuilds within the hour.
This page describes what has already happened. It is not investment advice and not a recommendation to buy or sell any security. Arthkar is not a SEBI-registered investment adviser or research analyst, and does not provide or arrange investment advice. Investments in securities are subject to market risk.
